semaglutide swisschems As demand for GLP-1 therapies grows, synthetic peptide versions of semaglutide are rapidly emerging. But manufacturing method matters: impurity profiles stability immunogenicity regulatory standards Takeaway: “Follow-on” GLP-1 Health Canada has approved the

2026 Update: In the SURMOUNT-5 head-to-head trial, tirzepatide produced ~47% more weight loss than semaglutide over 72 weeks

As the population of long-term GLP-1 users grows into the tens of millions, the market for these solutions will expand accordingly

The diverse approaches regarding the use of semaglutide for weight reduction highlight the necessity to guide physicians and standardize the long-term treatment regimen in anti-obesity medicine

Quick Answer: Semaglutide causes burping in approximately 7% of patients by slowing gastric emptying, which increases stomach pressure and triggers gas release

Based on glycemic response and tolerability, the dose may be increased to 1 mg or 2 mg weekly